Immuron - ADR (IMRN) Peer Comparison
$1.16
$-0.03
(-2.52%)
As on 30-Sep-2026 14:22EDT
Market cap
$9 Mln
Revenue (TTM)
$11 Mln
P/E Ratio
--
P/B Ratio
1.2
Div. Yield
0 %
Edit
| Immuron - ADR (IMRN) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
9 | 2,804 | 2,423 | 1,963 | 727 |
Revenue ($ Mln) |
8 | 450 | 549 | 121 | -- |
Net Profit ($ Mln) |
-3.75 | -188.21 | 17.88 | -57.76 | -175.85 |
Net Margin (%) |
-71.92 | -41.86 | 3.26 | -47.82 | -- |
RoE (%) |
-39.44 | -28.46 | 1.43 | -9.91 | -106.84 |
Price to Earnings |
-- | -- | 139.40 | -- | -- |
Price-To-Book |
1.21 | 4.89 | 1.98 | 3.50 | 4.97 |
Income Statement ($ Mln)
| Immuron - ADR (IMRN) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
7.55 | -- | -- | 120.79 | -- |
|
Cost of Revenue
|
2.68 | -- | -- | 19.21 | -- |
|
Gross Profit
|
4.87 | -- | -- | 101.58 | -- |
|
Operating Expenses
|
9.50 | -- | -- | 153.08 | -- |
|
Operating Profit (EBIT)
|
-4.63 | -- | -- | -51.50 | -- |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-4.36 | -- | -- | -57.14 | -- |
|
Provision for Tax
|
-0.61 | -- | -- | 0.62 | -- |
|
Profit after Tax (Net Income)
|
-3.75 | -- | -- | -57.76 | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Immuron - ADR (IMRN) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
11.01 | -- | -- | 568.41 | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.20 | -- | -- | 123.56 | -- |
|
Current Liabilities
|
1.79 | -- | -- | 81.11 | -- |
|
Total Liabilities
|
12.99 | -- | -- | 773.08 | -- |
Assets ($ Mln)
| Immuron - ADR (IMRN) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.19 | -- | -- | 575.59 | -- |
|
Current Assets
|
12.80 | -- | -- | 197.49 | -- |
|
Total Assets
|
12.99 | -- | -- | 773.08 | -- |
|
Total Debt*
|
-- | -- | -- | 127.33 | -- |
|
Net Current Assets
|
-- | -- | -- | 116.38 | -- |
Cashflow ($ Mln)
| Immuron - ADR (IMRN) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-3.00 | -- | -- | -43.83 | -- |
|
Cash Flow from Investing Activities
|
2.97 | -- | -- | -1.02 | -- |
|
Cash from Financing Activities
|
6.35 | -- | -- | -15.33 | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Immuron - ADR (IMRN) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-39.20 | -- | -- | -8.13 | -- |
|
ROE (%)
|
-39.44 | -- | -- | -9.91 | -- |
|
ROA (%)
|
-32.53 | -- | -- | -7.42 | -- |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-49.77 | -- | -- | -47.82 | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Immuron - ADR (IMRN) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.04 | -- | -- | 6.02 | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
28.01 | -- | -- | 43.45 | -- |
|
EPS Growth (%)
|
0.48 | -- | -- | 0.45 | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Immuron - ADR (IMRN) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-2.30 | -- | -- | -30.40 | -- |
|
Price / Book Value
|
0.78 | -- | -- | 3.09 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
0.09 | -- | -- | -42.81 | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Immuron - ADR (IMRN) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-- | -- | -- | 0.22 | -- |
|
Short term debt to equity ratio
|
-- | -- | -- | 0.02 | -- |
|
Current Ratio
|
7.17 | -- | -- | 2.43 | -- |
|
Quick Ratio
|
5.90 | -- | -- | 2.09 | -- |
|
Interest Coverage
|
-- | -- | -- | -2.15 | -- |
Operating Efficiency Ratios
| Immuron - ADR (IMRN) | Zai Lab - ADR | HUTCHMED (China) - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
16.57 | -- | -- | 47.74 | -- |
|
Asset Turnover
|
0.65 | -- | -- | 0.16 | -- |
|
Receivable days
|
49.42 | -- | -- | 109.66 | -- |
|
Inventory Days
|
275.87 | -- | -- | 478.70 | -- |
|
Payable days
|
196.01 | -- | -- | 509.43 | -- |
|
Cash Conversion Cycle
|
129.28 | -- | -- | 78.92 | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
